Amgen Accrued liabilities decreased by 228.0% to -$959.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.7%, from -$874.00M to -$959.00M. Over 2 years (FY 2022 to FY 2025), Accrued liabilities shows an upward trend with a 126.8% CAGR.
Fluctuations reflect changes in the timing of operational expense recognition and payment cycles.
This represents the net change in short-term obligations for expenses that have been incurred but not yet invoiced or pa...
Standard line item in the operating section of the cash flow statement.
other_increase_decrease_in_accrued_liabilities| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $24.25M | $24.25M | $24.25M | $24.25M | -$230.00M | $581.00M | $884.00M | -$1.05B | $693.00M | -$275.00M | $728.00M | -$874.00M | $824.00M | -$200.00M | $749.00M | -$959.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | <-999% | +352.6% | +52.2% | -219.2% | +165.7% | -139.7% | +364.7% | -220.1% | +194.3% | -124.3% | +474.5% | -228.0% |
| YoY Change | — | — | — | — | <-999% | >999% | >999% | -358.3% | +19.3% | — | -17.6% | +17.1% | +18.9% | +27.3% | +2.9% | -9.7% |